TMCnet

"LEQEMBI®" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aß) monoclonal antibody “LEQEMBI ® ” (generic name: lecanemab) has been approved for once every four weeks ...

Eureka’s ARTEMIS® CAR T Cells Show Breakthrough Potential in Solid Tumors in NCI-Led Study Published in Cell Reports Medicine

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies for cancer, today announced the publication of a peer-reviewed study titled "Antibody–Gamma/Delta T ...

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...
eLife

Contrasting roles for IKK regulated inflammatory signalling pathways for development and maintenance of type 1 and adaptive γδ T cells

This study provides valuable insights into the role of the NF-kB and IKK signaling pathways in γδ T cell development and survival, using robust genetic mouse models. While the research is ...